Search clinical trials for: Hepatic Impairment,

Total 10222 results

Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

United States
R-Pharm
Ascent

Completed

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

Hepatic Impairment

Georgia, Russian Federation
Pfizer

Completed

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

Hepatic Impairment

United States
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment

Hepatic Impairment

United States
Dong-A Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function (udenafil)

Hepatic Impairment

Korea, Republic of
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Affiliated Hospital of Zhengzhou University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions

Chronic Renal Impairment

China
Bayer

Completed

Study of Copanlisib in Hepatic or Renal Impairment

Hepatic Insufficiency, Renal Insufficiency

Germany, Romania
AstraZeneca

Recruiting

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Hepatic Impairment

United States
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Hepatic Impairment

China
CTI BioPharma
PPD

Recruiting

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Hepatic Impairment

United States
Eisai Co., Ltd.

Recruiting

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

Japan
Novartis Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants

Hepatic Impairment

Hungary
Chipscreen Biosciences, Ltd.

Completed

Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

China
SK Life Science, Inc.

Completed

Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Hepatic Impairment

Poland, Slovakia
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States
Reata, a wholly owned subsidiary of Biogen

Completed

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Pfizer

Completed

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

Hepatic Impairment

China
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

Hepatic Impairment

United States
Janssen Research & Development, LLC

Terminated

A Study of JNJ-53718678 in Participants With Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of BAF312 in Patients With Hepatic Impairment

Hepatic Impairment

Hungary, Russian Federation
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment

Hepatic Impairment

China
Novartis Pharmaceuticals

Completed

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects

Hepatic Impairment

Germany, United States, Hungary
Novartis Pharmaceuticals

Terminated

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Janssen Sciences Ireland UC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

Hepatic Impairment

Germany
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Pfizer

Completed

A Hepatic Impairment Study for PF-04965842.

Hepatic Impairment

United States
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects

Healthy Volunteers | Hepatic Impairment of Moderate Child Pugh Category

France, Hungary
Akebia Therapeutics

Completed

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States
Hoffmann-La Roche

Completed

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Hepatic Impairment

Czechia, Slovakia
H. Lundbeck A/S

Completed

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

Hepatic Impairment

Germany
Agios Pharmaceuticals, Inc.

Completed

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Hepatic Impairment

United States
Allergan

Completed

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Hepatic Impairment

United States
PTC Therapeutics

Completed

A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics

Hepatic Impairment

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Trius Therapeutics LLC

Completed

A PK and Safety Study in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Alkermes, Inc.

Completed

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Wockhardt

Completed

Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Hepatic Impairment

United States
ApoPharma

Completed

An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers

Hepatic Impairment

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment

Hepatic Impairment

United States
AVEO Pharmaceuticals, Inc.

Completed

A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers

Hepatic Impairment

United States
Movetis

Completed

Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment (HI)

Hepatic Impairment

Russian Federation
VIVUS LLC
Covance; Sentrx

Completed

A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

Hepatic Impairment

United States

3

Subscribe